Todd Cooper, DO, discusses The Seattle Children’s Hospital's recently launched program for patients with high-risk leukemia.
Matthew Davids, MD, discusses the novel agents available for the treatment of chronic lymphocytic leukemia as well as strategies for sequencing monotherapies and administering combination regimens in this disease setting.
Timothy Showalter, MD, discusses why brachytherapy is being used less and less for the treatment of cervical cancer and the importance of incentivizing quality care in payment policies.
Steve Miller, CMO, discusses his thoughts on the recently approved gene therapy for acute lymphoblastic leukemia, the accompanying price tag of said therapy, and the challenges the health care system faces paying for gene therapies and making them accessible to patients.
Michael Kelley, MD, discusses the Precision Oncology Program, including updates in gene panel testing, clinical trial accessibility, and additional programs to improve oncology care for veterans.
Ray Page, DO, PhD, and Abby Wright, Biodesix, discuss the importance of prognostic tests—such as Veristrat—in clinical pathways and in aiding achievement of quality measures in the Oncology Care Model.
Lucio N Gordan, MD, discusses his recent report for the Community Oncology Alliance and the implications that setting has on cost of cancer for patients.
Natalie S Callander, MD, discusses her presentation at the latest NCCN Congress on Hematologic Malignancies regarding individualized treatment for patients with relapsed or refractory multiple myeloma.